Progress with a Price - excellent session on the search for breast cancer patients for whom less is more #ASCO2018

Original Article: Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (SOFT/TEXT) nej.md/2kI18Ju Editorial: Endocrine Adjuvant Therapy for Localized Breast Cancer nej.md/2Hd9VM5 #ASCO18

SOFT/TEXT trial update: Addition of Ovarian Function Suppression leads to improment in Distant Recurrence Free Survival for patients who received adjuvant chemo i.e high risk determined by investigators #ASCO18

Some festive ridiculousness at the Ottawa Hospital Cancer Centre Christmas Party! #ChristmasIsComing OttawaMedOnc

Thanks to all for the great discussion on avastin complications & TPN in advanced cancer at M&M today! OttawaMedOnc jamanetwork.com/journals/jama/…

Follow up to MBTI personality test for those interested! 16personalities.com OttawaMedOnc

Thanks to the Oncofertility consortium for awarding me a scholarship to attend their annual meeting for the first time - I leave inspired to continue the amazing work! #oncofertility #breastcancer

Among teenage males undergoing cancer treatment, having children was ranked above making money, owning a home, faith, friends, or romantic relationships. Yet, only 43.8% banked sperm before undergoing cancer treatment. #oncofertility READ MORE: buff.ly/2zNEGHY

The New and Old of Cancer Emergencies - Dr. Rory Connolly reviews the most common complications of cancer treatments in 2017, as well as novel approaches to Febrile Neutropenia. emottawablog.com/2017/11/the-ne…

Dr. Gray sharing data on chemotherapy schedule impact on breast cancer outcome - overall improved outcome with dose dense approach #SABCS17

Phase II trial of Sacituzumab in TNBC - RR 34% ; Duration of response: 7.6m; PFS 5.5m. Impressive efficacy in heavily pre-Tx TNBC #SABCS17

Monaleesa 7 results by Debu Tripathy, MD - first line Ribociclib in pre/peri-menopausal HR+ve MBC. Improved PFS (HR 0.55) #SABCS17

Academic Half Day - The Hallmarks of Cancer: Next Generation OttawaMedOnc goo.gl/images/whunm1 cell.com/cell/fulltext/…

ABCSG-16 : No improvement with 5 years of AI vs. 2 years of AI after initial 5 years of endocrine Tx. #SABCS17

TEXT and SOFT combined analysis (med f/up 9 yr): Maintained benefit for OFS and Exemestane in DFS for pts undergoing chemo #SABCS17

GnRHa May Protect Ovarian Function, Preserve Fertility in Premenopausal Women With Early-Stage Breast Cancer shar.es/1Mdak4 via OncLive.com #Oncofertility #breastcancer #sabcs17

OttawaMedOnc

Delighted to speak about the importance of funding breast cancer research at the Mother’s Day Walk today #canadianbreastcancersociety